Mustang Bio (MBIO) Competitors $4.32 -0.37 (-7.89%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$4.36 +0.04 (+0.81%) As of 01/31/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MBIO vs. NERV, AFMD, SPRB, CING, NNVC, ACXP, NRSN, CRVO, AIM, and IMNNShould you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Minerva Neurosciences (NERV), Affimed (AFMD), Spruce Biosciences (SPRB), Cingulate (CING), NanoViricides (NNVC), Acurx Pharmaceuticals (ACXP), NeuroSense Therapeutics (NRSN), CervoMed (CRVO), AIM ImmunoTech (AIM), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry. Mustang Bio vs. Minerva Neurosciences Affimed Spruce Biosciences Cingulate NanoViricides Acurx Pharmaceuticals NeuroSense Therapeutics CervoMed AIM ImmunoTech Imunon Minerva Neurosciences (NASDAQ:NERV) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership. Which has more risk & volatility, NERV or MBIO? Minerva Neurosciences has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Do analysts rate NERV or MBIO? Minerva Neurosciences currently has a consensus price target of $5.00, indicating a potential upside of 116.45%. Mustang Bio has a consensus price target of $100.00, indicating a potential upside of 2,214.81%. Given Mustang Bio's stronger consensus rating and higher possible upside, analysts clearly believe Mustang Bio is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NERV or MBIO more profitable? Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% Mustang Bio N/A N/A -172.89% Does the media favor NERV or MBIO? In the previous week, Mustang Bio had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 5 mentions for Mustang Bio and 3 mentions for Minerva Neurosciences. Mustang Bio's average media sentiment score of 0.70 beat Minerva Neurosciences' score of 0.29 indicating that Mustang Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mustang Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in NERV or MBIO? 34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by insiders. Comparatively, 0.5% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor NERV or MBIO? Minerva Neurosciences received 178 more outperform votes than Mustang Bio when rated by MarketBeat users. However, 64.26% of users gave Mustang Bio an outperform vote while only 57.07% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34757.07% Underperform Votes26142.93% Mustang BioOutperform Votes16964.26% Underperform Votes9435.74% Which has preferable earnings & valuation, NERV or MBIO? Minerva Neurosciences is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M-$0.44-5.25Mustang BioN/AN/A-$51.60M-$78.00-0.06 SummaryMustang Bio beats Minerva Neurosciences on 8 of the 14 factors compared between the two stocks. Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBIO vs. The Competition Export to ExcelMetricMustang BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.67M$6.87B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E Ratio-0.067.6680.0317.24Price / SalesN/A320.221,259.7283.26Price / CashN/A73.5045.9637.70Price / Book6.455.275.124.70Net Income-$51.60M$136.98M$111.40M$224.47M7 Day Performance-9.81%-0.84%2.30%-0.19%1 Month Performance-51.19%-0.02%3.13%0.57%1 Year Performance-93.96%7.51%24.60%20.35% Mustang Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBIOMustang Bio2.9789 of 5 stars$4.32-7.9%$100.00+2,214.8%-94.0%$4.67MN/A-0.06100Short Interest ↓NERVMinerva Neurosciences3.5026 of 5 stars$2.31+6.9%$5.00+116.5%-72.7%$16.15MN/A-5.259Analyst ForecastShort Interest ↑High Trading VolumeAFMDAffimed4.0857 of 5 stars$1.00-9.5%$13.50+1,256.8%-81.7%$16.02M$8.95M0.00200Short Interest ↓News CoverageGap UpSPRBSpruce Biosciences3.6124 of 5 stars$0.38-0.8%$3.90+929.0%-89.8%$15.65M$10.09M-0.4020Short Interest ↓CINGCingulate2.9652 of 5 stars$4.75-6.5%$12.00+152.6%+46.8%$15.42MN/A0.0020Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageNNVCNanoViricidesN/A$1.08-3.2%N/A+7.1%$15.00MN/A-1.4120ACXPAcurx Pharmaceuticals3.0099 of 5 stars$0.84-3.4%$12.00+1,325.2%-77.7%$14.34MN/A-0.773Short Interest ↓News CoverageNRSNNeuroSense TherapeuticsN/A$1.02-7.7%N/A-11.2%$13.88MN/A-1.5910Short Interest ↑Gap UpCRVOCervoMed3.4865 of 5 stars$2.23-3.5%$42.00+1,784.3%-73.6%$13.76M$7.14M0.004Short Interest ↓News CoverageAIMAIM ImmunoTech2.1251 of 5 stars$0.21-1.0%$2.75+1,197.2%-51.3%$13.52M$200,000.00-0.4520Gap DownIMNNImunon2.7267 of 5 stars$0.92-3.9%$20.50+2,128.3%+71.5%$13.47M$500,000.00-0.4930Short Interest ↑Gap Up Related Companies and Tools Related Companies NERV Alternatives AFMD Alternatives SPRB Alternatives CING Alternatives NNVC Alternatives ACXP Alternatives NRSN Alternatives CRVO Alternatives AIM Alternatives IMNN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MBIO) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
